{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-026241","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.242238+00:00","generated_at":"2026-06-14T07:27:29.498257+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus ARC-7 Phase 2 data: domvanalimab arms reduce PFS risk 28-33% in NSCLC","bullets":["Doublet (domvanalimab+zimberelimab) showed 33% PFS risk reduction (HR 0.67) vs zimberelimab monotherapy in PD-L1≥50% NSCLC.","Median PFS: 5.4 mo (Z), 9.3 mo (DZ), 9.9 mo (EDZ); 12-month PFS rates 25%, 41%, 44%.","ORR: Z 30%, DZ 40%, EDZ 44%; median DoR not reached for DZ, 23.7 mo for EDZ.","No unexpected safety signals; infusion-related reactions low (4-12%) across arms.","Data from 150-patient randomized Phase 2 at ~18-month median follow-up."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-026241","json":"https://secwatch.observer/filing/0000950170-23-026241.json","markdown":"https://secwatch.observer/filing/0000950170-23-026241.md","text":"https://secwatch.observer/filing/0000950170-23-026241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023026241/0000950170-23-026241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023026241/rcus-20230603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:27:29.498257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}